首页> 外文期刊>Hepato-gastroenterology. >Preoperative transarterial chemoembolization for hepatocellular carcinoma
【24h】

Preoperative transarterial chemoembolization for hepatocellular carcinoma

机译:术前经肝动脉化疗栓塞治疗肝细胞癌

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: The effects of transarterial chemoembolization (TACE) prior to hepatectomy for patients with hepatocellular carcinoma (HCC) are controversial. Methodology: Clinicopathological profiles and prognosis were compared between patients who underwent hepatic resection following preoperative TACE (Group A, 69 patients) or only resection (Group B, 158 patients). Univariate and multivariate analyses were used to evaluate whether TACE influenced patient prognosis. Results: Profiles of Group A were comparable with those of Group B except for younger age, higher frequency of major hepatectomy, higher incidence of positive surgical margin, vascular invasion and poorly differentiated HCC. Overall survival was significantly worse in Group A than in Group B (5year survival rate; 29% vs. 69%; p<0.001). A subset of patients in Group A with complete tumor necrosis by TACE showed comparable survival with Group B. Multivariate analysis revealed that preoperative TACE (hazard ratio (HR)=4.3; 95% confidential interval (CI), 2.8-6.6), non-anatomic resection (HR=1.6; 95% CI, 1.1-2.4), blood loss >1L (HR=1.8; 95% CI=Ll-2.8) and vascular invasion (HR=2.3; 95% CI=1.4-3.6) were independent predictors of poor survival. Preoperative TACE was also an independent predictor of extrahepatic metastases (odds ratio, 2.8; 95% CI=Ll-7.1). Conclusions: Preoperative TACE should not be routinely applied for HCC.
机译:背景/目的:肝癌(HCC)患者肝切除术前经动脉化学栓塞术(TACE)的疗效尚存争议。方法:比较术前TACE进行肝切除术的患者(A组,69例)或仅切除术(B组,158例)的临床病理特征和预后。使用单因素和多因素分析来评估TACE是否影响患者的预后。结果:除年龄较小,大肝切除术频率更高,手术切缘阳性率较高,血管浸润和HCC分化不良外,A组的概况与B组相似。 A组的总生存率显着低于B组(5年生存率; 29%比69%; p <0.001)。多因素分析显示,术前TACE(危险比(HR)= 4.3; 95%可信区间(CI),2.8-6.6),非解剖切除(HR = 1.6; 95%CI,1.1-2.4),失血> 1L(HR = 1.8; 95%CI = L1-2.8)和血管浸润(HR = 2.3; 95%CI = 1.4-3.6)生存不良的独立预测因素。术前TACE也是肝外转移的独立预测因子(比值比为2.8; 95%CI = L1-7.1)。结论:术前TACE不应常规应用于肝癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号